Ascendis Will Take On Daily Genotropin With Weekly Skytrofa
Company Will Try To Assert Superiority Claim
Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.
